Literature DB >> 30982344

Clinical trials in molecular radiotherapy-Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018.

Nadia Falzone1, Rebecca Gregory2, Matthew Aldridge3, Samantha Ya Terry4, Glenn Flux2.   

Abstract

It has been almost a decade since the commentary Molecular radiotherapy - the radionuclide raffle? by Gaze and Flux (2010) . The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI-CTRad (Clinical Trials in Molecular Radiotherapy-Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI-CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.

Mesh:

Substances:

Year:  2019        PMID: 30982344      PMCID: PMC6724631          DOI: 10.1259/bjr.20190117

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  13 in total

1.  Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.

Authors:  U Mallick; C Harmer; A Hackshaw; L Moss
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-02-07       Impact factor: 4.126

2.  Molecular radiotherapy--the radionuclide raffle?

Authors:  M N Gaze; G D Flux
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

Review 3.  The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair.

Authors:  R K Sachs; P Hahnfeld; D J Brenner
Journal:  Int J Radiat Biol       Date:  1997-10       Impact factor: 2.694

4.  Monte Carlo Evaluation of Auger Electron-Emitting Theranostic Radionuclides.

Authors:  Nadia Falzone; José M Fernández-Varea; Glenn Flux; Katherine A Vallis
Journal:  J Nucl Med       Date:  2015-07-23       Impact factor: 10.057

5.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

6.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

Authors:  Martin Schlumberger; Bogdan Catargi; Isabelle Borget; Désirée Deandreis; Slimane Zerdoud; Boumédiène Bridji; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Danielle Benisvy; Claire Bournaud; Françoise Bonichon; Catherine Dejax; Marie-Elisabeth Toubert; Sophie Leboulleux; Marcel Ricard; Ellen Benhamou
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

7.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

8.  Absorbed dose evaluation of Auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values.

Authors:  Nadia Falzone; Boon Q Lee; José M Fernández-Varea; Christiana Kartsonaki; Andrew E Stuchbery; Tibor Kibédi; Katherine A Vallis
Journal:  Phys Med Biol       Date:  2017-01-19       Impact factor: 3.609

9.  SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.

Authors:  Jonathan Wadsley; Rebecca Gregory; Glenn Flux; Kate Newbold; Yong Du; Laura Moss; Andrew Hall; Louise Flanagan; Sarah R Brown
Journal:  Br J Radiol       Date:  2017-03-14       Impact factor: 3.039

10.  213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.

Authors:  Mike Sathekge; Otto Knoesen; Marian Meckel; Moshe Modiselle; Mariza Vorster; Sebastian Marx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.